Diseases /
Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Overview
NCI Definition: A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed. This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver. The prognosis of this tumor is poor. [1]
Combined hepatocellular carcinoma and cholangiocarcinomas most frequently harbor alterations in TP53, PBRM1, CDKN2B, CDKN2A, and BAP1 [2].
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, CDKN2B Loss, and CDKN2A Loss are the most common alterations in combined hepatocellular carcinoma and cholangiocarcinoma [2].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.